Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Essential thrombocythemia.

Claire N Harrison1, Anthony R Green

  • 1Department of Haematology, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK. claire.harrison@gstt.sthames.nhs.uk

Hematology/Oncology Clinics of North America
|October 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.

HemaSphere·2026
Same author

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026
Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026
Same author

Genomic evolution and natural history of myeloproliferative neoplasms on therapy.

Cancer discovery·2026
Same author

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Cancer medicine·2026
Same author

Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction.

Expert opinion on pharmacotherapy·2026
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Essential thrombocythemia, a myeloproliferative disorder, lacks a definitive diagnostic test, suggesting patient heterogeneity. This review covers essential thrombocythemia diagnosis, features, prognosis, and management strategies.

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Essential thrombocythemia is a myeloproliferative neoplasm.
  • Current diagnostic criteria for essential thrombocythemia may lead to patient heterogeneity.
  • There is no single pathognomonic diagnostic test for essential thrombocythemia.

Purpose of the Study:

  • To discuss the diagnostic criteria for essential thrombocythemia.
  • To review the clinical features and prognosis of essential thrombocythemia.
  • To outline the current management strategies for essential thrombocythemia.

Main Methods:

  • Literature review of diagnostic criteria.
  • Analysis of clinical features and prognostic factors.
  • Summary of established management guidelines.

Related Experiment Videos

Main Results:

  • Essential thrombocythemia diagnosis relies on a combination of clinical and laboratory findings.
  • Patient prognosis varies significantly based on risk stratification.
  • Management aims to reduce thrombotic risk and control platelet counts.

Conclusions:

  • Essential thrombocythemia is a complex disorder requiring careful diagnosis and risk assessment.
  • Personalized management strategies are crucial for improving patient outcomes.
  • Further research is needed to refine diagnostic criteria and therapeutic approaches.